Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
4
×
europe blog main
europe top stories
4
×
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
novartis
4
×
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gilead sciences
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
alzheimer's disease
astrazeneca
biogen
cancer drugs
covid-19
deals
What
bio
medicines
roundup
acquisitions
ceo
covid
daniel
drug
fda
gilead
ipo
o’day
sciences
activity
address
announced
approval
approvals
approves
biggest
biogen
blueprint
build
buy
cancer
carries
certain
clamped
collabs
company’s
deal
debut
delays
designed
developing
dyne’s
economic
fast
genetic
gilead’s
Language
unset
4
×
Current search:
novartis
×
unset
×
cancer
×
" europe top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More